Regarding recurrence-mediated pathways, beyond amplified thrombin generation or impaired fibrinolysis, patients with major congenital thrombophilia (protein C, protein S, or antithrombin deficiencies) experience higher rates of recurrent VTE, including clinically silent events. The gene discussed is PROS1; the disease is thrombophilia.